Eli Lilly Beats Estimates as ServiceNow Tumbles — SkimNews
Get the Finance newsletter
Daily finance — markets, central banks, M&A, the prints that move money. Free.
- ServiceNow missed Q3 earnings, sending its shares plunging after the disappointing financial report.
- Eli Lilly beat estimates and raised its sales outlook as demand for Zepbound and Mounjaro drove higher revenue and surging profits.
Why it matters: For ServiceNow, the Q3 miss translated directly into a share-price plunge. For Eli Lilly, three other headlines converge on a better outcome—an estimate beat, a raised sales outlook, higher revenue and surging profits tied to demand for Zepbound and Mounjaro—making the live update broader than one company’s sell-off.
Ask SkimNews
